T1D Exchange Announces Population Health Surveillance Study of COVID-19 in Individuals with Type 1 Diabetes
T1D Exchange today announced the launch of a population health surveillance study of individuals with type 1 diabetes (T1D) who are suspected or confirmed to have contracted Coronavirus Disease 2019 (COVID-19). The results of the study will be used to better understand the etiology and potential outcomes in COVID-19 patients and inform future clinical quality improvement activities to better respond to the global pandemic.
T1D Exchange Coordinates With Local Authorities to Provide Hand Sanitizer and Medical Supplies
With the COVID-19 coronavirus continuing to spread and disrupt daily life, supply chains and medical operations, there is an increasing need for access to vital basics such as hand sanitizer. Through an ongoing partnership with MassBio, we were able to answer the call – along with numerous other organizations – as to how we can …
Real World Evidence: What It Means and Why it Matters for Type 1 Diabetes
People living with type 1 diabetes learn, in many ways, to be research scientists and investigators of their own lives. We learn how slices of pizza or a plate of spaghetti affects our blood sugar, and how to mediate those effects with multiple boluses of insulin or a long-lasting dose. We discover precisely how much sugar we need to stay steady during an intense workout session.
In doing so, we begin to learn about the meaning and applications of real-world data and evidence. Modern medical and scientific research takes several different approaches to investigation, from randomized, controlled clinical trials to longitudinal, observational studies that examine how people live with various conditions and therapies in the real world.
The COVID-19 Coronavirus: A Primer for People With Type 1 Diabetes
The most widely-reported and potentially momentous story of the moment is the novel COVID-19 coronavirus, a respiratory pathogen that has already infected at least 100,000 people around the globe and killed at least 4,300.
T1D Exchange Study: Sleep Loss Reported as Most Frequent Daily Hurdle in Life with Type 1 Diabetes
Research on type 1 diabetes often centers on its health impacts, but people with type 1 diabetes have long said that such research only paints half of the picture, and that there are many more hidden costs to life with the condition.
Diasome Announces Positive Results for HDV Insulin Additive to Manage Blood Sugar
Diasome Pharmaceuticals announced positive results this week from a Phase 2 study of its injectable hepatocyte directed vesicle (HDV) additive for insulin in patients with type 1 diabetes. The news could prove a major step forward for therapies that aim to improve and optimize the way insulin is used and metabolized by the body. In …
2020 Data: Current Insights from the T1D Exchange Registry
The T1D Exchange Registry launched last year, and it’s begun to provide a fascinating and vital look into some of the more detailed aspects of life with type 1 diabetes. From your age of diagnosis to frequency of testing, we’ve learned more about how you’re living, working, and caring for diabetes across the country.
Join our mailing list for more about T1D